Revuforj
My Prescription
Payment
Select pharmacy
$22,317.37
Print or send this coupon to your phone
AlbertsonsPowered byAbout Revuforj
Drug Details
Revumenib is a medication specifically prescribed for the treatment of acute leukemia, a type of cancer. It functions by halting or slowing down the proliferation of cancer cells, thereby helping to manage the disease effectively.
Price history for Revuforj
30 Tablets, 110MG
Average retail price for Revuforj
Average SaveHealth price for Revuforj
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Revuforj dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 25MG | 30 Tablets | $11,303.89 | $376.80 |
| 110MG | 30 Tablets | $22,317.37 | $743.91 |
| 160MG | 30 Tablets | $22,317.37 | $743.91 |
Revuforj FAQs
Revuforj is used for the treatment of anemia in patients with chronic kidney disease. It helps to increase red blood cell production and improve hemoglobin levels.
The cost of Revuforj can vary depending on factors such as the pharmacy, location, insurance coverage, and any available discounts or patient assistance programs. It is recommended to contact local pharmacies or consult with a healthcare provider for the most accurate and up-to-date pricing information.
Revuforj, also known as Vutrisiran, is a medication used for the treatment of hereditary transthyretin-mediated amyloidosis. In clinical trials, Revuforj demonstrated a significant improvement in neuropathy symptoms and quality of life for patients. The success rate can vary depending on individual patient factors, but the trials showed positive outcomes in a majority of participants. For specific success rates, it is advisable to refer to the latest clinical trial data or consult a healthcare professional.